Type 2 diabetes and vascular complications: A pathophysiologic view

Biomedical Research

Volumn 21, Issue 2, 2010, Pages 147-155

  Ahmed, Khaled A ^a,b   Muniandy, Sekaran ^a   Ismail, Ikram S ^c  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b IBB UNIVERSITY   (Yemen)

^c UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

Author keywords

Diabetes mellitus; Hyperglycemia; Metabolic disorders; Nephropathy; Neuropathy

Indexed keywords

ADVANCED GLYCATION END PRODUCT; POLYOL; PROTEIN KINASE C;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIABETOGENESIS; DISEASE ASSOCIATION; DISORDERS OF CARBOHYDRATE METABOLISM; DYSLIPIDEMIA; FATALITY; GENETIC PREDISPOSITION; HEREDITY; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEFICIENCY; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PERIPHERAL VASCULAR DISEASE; PREVALENCE; RISK FACTOR; VASCULAR DISEASE;

EID: 77956233033     PISSN: 0970938X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (96)

1. Groop LC, Tuomi T. Non-insulin-dependent diabetes mellitus- a collision between thrifty genes and an afflu-ent society. Ann Med 1997; 29: 37-53.
2. Weyer C, Bogardus C, Mott DM, et al. The natural history of insulin secretory dysfunction and insulin re-sistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-794.
3. Lebovitz HE. Diagnosis, classification, and pathogene-sis of diabetes mellitus. J Clin Psychiatry 2001; 62 (Suppl 27): 5-9.
4. Owen K, Hattersley AT. Maturity-onset diabetes of the young: from clinical description to molecular genetic characterization. Best Pract Res Clin Endocrinol Metab 2001; 15: 309-323.
5. Kahn CR, Vicent D, Doria A. Genetic of non-insulin-dependant (Type-II) diabetes mellitus. Ann Rev Med 1996; 47: 509-531.
6. Tuomi T, Carlsson AL, Li H, et al. Clinical and ge-netic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 1999; 48: 150-157.
7. Pozzilli P, Di Mario U. Autoimmune diabetes not re-quiring insulin at diagnosis (latent autoimmune diabe-tes of the adult): definition, characterization, and poten-tial prevention. Diabetes Care 2001; 24: 1460-1467.
8. Bagust A, Hopkinson PK, Maslove L, Currie CJ. The projected health care burden of Type 2 diabetes in the UK from 2000 to 2060. Diabet Med 2002; 19: 1-5.
9. Motala AA, Pirie FJ, Gouws E, Amod A, Omar MK. High incidence of Type 2 diabetes mellitus in South African Indians: a 10-year follow-up study. Diabet Med 2003; 20: 23-30.
10. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glu-cose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998; 21: 518-524.
11. International Diabetes Federation [IDF]. Diabetes e-Atlas. Retrieved June 20, 2005, from http://www.-eatlas.idf.org.
12. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications:estimates and projections to the year 2010. Diabet Med 1997; 14 (Suppl 5): S1-S85.
13. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-1431.
14. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glu-cose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998; 21: 518-524.
15. The Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe (DECODE) Study Group. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. BMJ 1998; 317: 371-375.
16. Sicree R, Shaw J, Zimmet P. The global burden of dia-betes, Diabetes and impaired glucose tolerance: preva-lence and projections. In: Gan D eds. Diabetes Atlas. 2nd ed. International Diabetes Federation, Brussels 2003; pp 15-71.
17. Gu D, Reynolds K, Duan X, et al. Prevalence of dia-betes and impaired fasting glucose in the Chinese adult population: International collaborative study of cardi-ovascular disease in Asia (InterASIA). D iabetologia 2003; 46: 1190-1198.18
18. Farnkvist LM, Lundman BM. Outcomes of diabe-tes care: a population-based study. Int J Qual Health Care 2003; 15: 301-317.
19. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
20. Taylor SI, Accili D, Imai Y. Insulin resistance or insu-lin deficiency. Which is the primary cause of NIDDM? Diabetes 1994; 43: 735-740.
21. Kahn BB, Rossetti L. Type 2 diabetes- who is conduct-ing the orchestra? Nat Genet 1998; 20: 223-225.
22. Kahn CR. Banting lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 1994; 43: 1066-1084.
23. Reaven GM. Banting lecture 1988. Role of insulin re-sistance in human disease. Diabetes 1988; 37: 1595-1607.
24. Kahn SE, Porte D. β-cell dysfunction in type 2 diabe-tes: pathophysiological and genetic bases. In: Scriver CR, Beaud et al., Sly WS, Valle D eds. The metabolic and molecular bases of inherited disease. McGraw-Hill, New York 2001; pp 1407-1431.
25. Eriksson J, Lindstrom J, Tuomiletho J. Potential for the prevention of type 2 diabetes. Br Med Bul 2001; 60: 183-199.
26. Leahy JL. Pathogenesis of type 2 diabetes mellitus. Arch Med Res 2005; 36: 197-209.
27. Groop L, Forsblom C, Lehtovirta M. Characterization of the Prediabetic State. Am J Hypertension 1997; 10: 172S-180S.
28. Bergman RN, Ader M. Free Fatty Acids and Patho-genesis of Type 2 Diabetes Mellitus. Trends Endocri-nol Metab 2000; 11: 362-368.
29. Hauner H. Insulin resistance and the metabolic syn-drome-a challenge of the new millenium. Eur J Clin Nutr 2002; 56 (Suppl 1): S25-S29.
30. Bonora E, Kiechl S, Willeit J, et al. Prevalence of insu-lin resistance in metabolic disorders. The Bruneck Study. Diabetes 1998; 47: 1643-1649.
31. Rantala AO, Kauma H, Lilja M, et al. Prevalence of the metabolic syndrome in drug-treated hypertensive pa-tients and control subjects. J Intern Med 1999; 45: 163-174.
32. Alberti KGM, Zimmet PZ for the WHO Consultation. Definition, diagnosis and classification of diabetes mel-litus and its complications. Part 1: Diagnosis and clas-sification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
33. Thom T, Haase N, Rosamond W, et al. Heart Disease and Stroke Statistics--2006 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113: e85-e151.
34. International Diabetes Federation. Diabetes and Car-diovascular Disease: Time to Act. Brussels: Interna-tional Diabetes Federation 2001.
35. Stary HC, Chandler AB, Dinsmore RE, et al. A defini-tion of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: A report from the Committee on Vascular Lesions of the Coun-cil on Atherosclerosis, American Heart Association. Circulation 1995; 92: 1355-1374.
36. Wingard DL, Barrett-Connor E. Heart disease and dia-betes. In: Harris M eds. Diabetes in America. 2nd ed. Bethesda, NIH NIDDK 1995; pp 429-456.
37. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol. 2004; 24: 816-823.
38. Bansilal S, Farkouh M, Fuster V. Role of insulin resis-tance and hyperglycemia in the development of athero-sclerosis. Am J Cardiol 2007; 99(4A): 6B-14B.
39. Haffner SM. Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol 2003; 92(4A): 18J-26J.
40. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999; 48: 937-942.
41. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005: At-lanta, GA: U.S. Department of Health and Human Ser-vices, Centers for Disease Control and Prevention, 2005.
42. Davidson MB. Diabetes mellitus: diagnosis and treat-ment. W.B. Saunders Co., Los Angeles, California 1998.
43. Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Me-tab Rev 1987; 3: 463-524.
44. Barrett-Connor EL, Cohn BA, Wingard DL, et al. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA 1991; 265: 627-631.
45. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: ex-ecutive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136.
46. Hanssen KF. Blood glucose control and microvascular and macrovascular complications in diabetes. Diabetes 1997; 46 (Suppl.2): S101-S103.
47. Laakso M. Cardiovascular disease and diabetes melli-tus. Eur Heart J 2000; 2 (Suppl D): D26-D28.
48. Standl E, Balletshofer B, Dahl B, et al. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 1996; 39: 1540-1545.
49. Lehto S, Ronnemaa T, Haffner SM, et al. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 1997; 46: 1354-1359.
50. Wei M, Gaskill SP, Haffner SM, et al. Effects of diabe-tes and level of glycemia on all-cause and cardiovascu-lar mortality. The San Antonio Heart Study. Diabetes Care 1998; 21: 1167-1172.
51. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular com-plications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-12.
52. Ron D, Kazanietz MG. New insights into the regulation of protein kinase C and novel phorbol ester receptors. FASEB J 1999; 13: 1658-76.
53. King GL, Ishii H, Koya D. Diabetic vascular dysfunc-tions: a model of excessive activation of protein kinase C. Kidney Int Suppl 1997; 60: S77-S85.
54. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47: 859-866.
55. Inoguchi T, Battan R, Handler E, et al. Preferential elevation of protein kinase C isoform beta II and dia-cylglycerol levels in the aorta and heart of diabetic rats: Differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 1992; 89: 11059-11063.
56. Giardino I, Brownlee M. The biochemical basis of mi-crovascular disease. In: Pickup J, Williams G eds. Textbook of diabetes. Blackwell Science, Oxford 1997; pp 42.1-42.16.
57. Takagi C, King GL, Takagi H, et al. Endothelin-1 ac-tion via endothelin receptors is a primary mechanism modulating retinal circulatory response to hyperoxia. Invest Ophthalmol Vis Sci 1996; 37: 2099-2109.
58. Candido R, Allen TJ. Haemodynamics in microvascu-lar complications in type 1 diabetes. Diabetes Metab Res Rev 2002; 18: 286-304.
59. Hawthorne GC, Bartlett K, Hetherington CS, et al. The effect of high glucose on polyol pathway activity and myoinositol metabolism in cultured human endothelial cells. Diabetologia 1989; 32: 163-66.
60. Greene DA, Lattimer SA, Sima AF. Sorbitol, phospho-inositides, and sodium-potassium-ATPase in the patho-genesis of diabetic complications. N Engl J Med 1987; 316: 599-606.
61. Harrison HE, Stribling D, Armstrong FM, et al. Aldose reductase in the etiology of diabetic complications: I. Introduction. J Diabetes Complicat 1989; 3: 6-11.
62. Harding JJ. Nonenzymatic covalent posttranslational modification of proteins in vivo. Adv Protein Chem 1985; 37: 247-334.
63. Vlassara H, Bucala R, Striker L. Biology of disease. Pathogenic effects of advanced glycosylation: bio-chemical, biologic, and clinical implications for diabe-tes and aging. Lab Invest 1994; 70: 138-151.
64. Vlassara H. Recent progress in advanced glycation end products and diabetic complications. Diabetes 1997; 46 (Suppl 2): S19-S25.
65. Schmidt AM, Hori O, Cao R, et al. RAGE. A novel cellular receptor for advanced glycation end products. Diabetes 1996; 45 (Suppl 3): S77-S80.
66. Cipollone F, Iezzi A, Fazia M, et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic con-trol. Circulation 2003; 108: 1070-1077
67. ε-(Carboxymethyl)lysine and Coronary Atherosclerosis-Associated Low Density Lipoprotein Abnormalities in Type 2 Diabetes: Current Status. J Clin Biochem Nutr 2009; 44: 14-27.
68. Beck-Nielsen H, Vaag A, Poulsen P, Gaster M. Meta-bolic and genetic influence on glucose metabolism in type 2 diabetic subjects--experiences from relatives and twin studies. Best Pract Res Clin Endocrinol Metab 2003; 17: 445-467.
69. Chen D, Wang MW. Development and application of rodent models for type 2 diabetes. Diabetes Obes Me-tab 2005; 7: 307-317.
70. Astrup A, Finer N. Redefining type 2 diabetes: 'diabe-sity' or 'obesity dependent diabetes mellitus'? Obes Rev 2000; 1: 57-59.
71. Felber JP, Golay A. Pathways from obesity to diabetes. Int J Obes Relat Metab Disord 2002; 26 (Suppl 2): S39-S45.
72. Klein R, Klein BE, Moss SE. Epidemiology of prolif-erative diabetic retinopathy. Diabetes Care 1992; 15: 1875-91.
73. Aiello LP, Gardner TW, King GL, et al. Diabetic reti-nopathy. Diabetes Care 1998; 21: 143-56.
74. Forrester JV, Knott RM. Pathogenesis of diabetic reti-nopathy and cataract. In: Pickup J, Williams G eds. Textbook of Diabetes. Blackwell Science, Oxford 1997; pp 45.1-45.19.
75. American Diabetes Association. Diabetic retinopathy. Position Statement. Diabetes Care 1998; 21 (Suppl 1): S47-S49.
76. O'Bryan GT, Hostetter TH. The renal hemodynamic basis of diabetic nephropathy. Semin Nephrol 1997; 17: 93-100.
77. Mogensen CE, Chachati A, Christensen CK, et al. Mi-croalbuminuria: an early marker of renal involvement in diabetes. Uremia Invest 1986; 9: 85-95.
78. Krolewski AS, Warram JH, Freire MB. Epidemiology of late diabetic complications. A basis for the devel-opment and evaluation of preventive programs. Endo-crinol Metab Clin North Am 1996; 25: 217-242.
79. American Diabetes Association. Diabetic Nephropathy. Position Statement. Diabetes Care 1998; 21 (Suppl 1): S50-S53.
80. Vinik AI, Holland MT, le Beau JM, et al. Diabetic neuropathies. Diabetes Care 1992; 15: 1926-75.
81. Sheetz MJ, King GL. Molecular understanding of hy-perglycemia.s adverse effects for diabetic complica-tions. JAMA 2002; 288: 2579-2588.
82. King's Fund Policy Institute Report, Commissioned by the British Diabetic Association. Counting the cost: the real impact of non insulin dependent diabetes. London, King's Fund 1996.
83. Feldman EL, Stevens MJ, Russell JW, et al. Diabetic neuropathy. In: Becker KL ed. Principles and practice of endocrinology and metabolism. Baltimore, Lippin-cott Williams & Wilkins 2001; pp 1391-1399.
84. Apfel SC. Nerve regeneration in diabetic neuropathy. Diabetes Obes Metab 1999; 1: 3-11.
85. Calcutt NA. Potential mechanisms of neuropathic pain in diabetes. Int Rev Neurobiol 2002; 50: 205-228.
86. Feldman EL, Stevens MJ, Russell JW. Diabetic periph-eral and autonomic neuropathy. In: Sperling MA eds. Contemporary endocrinology. Totowa, N.J, Humana Press 2002; pp 437-461.
87. United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
88. Vinik AI, Maser RE, Mitchell BD, et al. Diabetic auto-nomic neuropathy. Diabetes Care 2003; 26: 1553-1579.
89. Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987; 3: 463-524.
90. Creager MA, Lüscher TF, Cosentino F, et al. Diabetes and vascular disease: Pathophysiology, clinical conse-quences, and medical therapy: Part I. Circulation 2003; 108:1527-1532.
91. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570-2581.
92. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2002. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention 2003.
93. Finkelstein EA, Fiebelkorn IC, Wang G. National medical spending attributable to overweight and obe-sity: How much, and who's paying? Health Affairs 2003; W3: 219-226.
94. Finkelstein EA, Fiebelkorn IC, Wang G. State-level estimates of annual medical expenditures attributable to obesity. Obesity Research 2004; 12: 18-24.
95. Mbanya JC, Mbanya D. Diabetes cost in sub-Saharan Africa. J Cardiovasc Risk. 2003; 10: 191-193.
96. Guerci B, Drouin P, Grange V, et al. Self-monitoring of blood glucose significantly improves metabolic con-trol in patients with type 2 diabetes mellitus: the Auto-Surveillance Intervention Active (ASIA) study. Diabe-tes Metab 2003; 29: 587-594.